The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy 1 . Constitutive nuclear factor (NF)-kB and JAK kinase signalling promotes malignant cell survival in these lymphomas, but the genetic basis for this signalling is incompletely understood. Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling 2, 3 , and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumours. RNA interference screening revealed that MYD88 and the associated kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival. High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines. Notably, 29% of ABC DLBCL tumours harboured the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core. This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was observed in 9% of mucosa-associated lymphoid tissue lymphomas. At a lower frequency, additional mutations were observed in the MYD88 TIR domain, occurring in both the ABC and germinal centre B-cell-like (GCB) DLBCL subtypes. Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation. The L265P mutant promoted cell survival by spontaneously assembling a protein complex containing IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-kB signalling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-b. Hence, the MYD88 signalling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MYD88 mutations.
1
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains the least curable form of this malignancy despite recent advances in therapy 1 . Constitutive nuclear factor (NF)-kB and JAK kinase signalling promotes malignant cell survival in these lymphomas, but the genetic basis for this signalling is incompletely understood. Here we describe the dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling 2, 3 , and the discovery of highly recurrent oncogenic mutations affecting MYD88 in ABC DLBCL tumours. RNA interference screening revealed that MYD88 and the associated kinases IRAK1 and IRAK4 are essential for ABC DLBCL survival. High-throughput RNA resequencing uncovered MYD88 mutations in ABC DLBCL lines. Notably, 29% of ABC DLBCL tumours harboured the same amino acid substitution, L265P, in the MYD88 Toll/IL-1 receptor (TIR) domain at an evolutionarily invariant residue in its hydrophobic core. This mutation was rare or absent in other DLBCL subtypes and Burkitt's lymphoma, but was observed in 9% of mucosa-associated lymphoid tissue lymphomas. At a lower frequency, additional mutations were observed in the MYD88 TIR domain, occurring in both the ABC and germinal centre B-cell-like (GCB) DLBCL subtypes. Survival of ABC DLBCL cells bearing the L265P mutation was sustained by the mutant but not the wild-type MYD88 isoform, demonstrating that L265P is a gain-of-function driver mutation. The L265P mutant promoted cell survival by spontaneously assembling a protein complex containing IRAK1 and IRAK4, leading to IRAK4 kinase activity, IRAK1 phosphorylation, NF-kB signalling, JAK kinase activation of STAT3, and secretion of IL-6, IL-10 and interferon-b. Hence, the MYD88 signalling pathway is integral to the pathogenesis of ABC DLBCL, supporting the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MYD88 mutations.
The current molecular taxonomy of DLBCL distinguishes three main subtypes: ABC, GCB and primary mediastinal B-cell lymphoma (PMBL) 4 . Current therapy is least successful in ABC DLBCL, achieving less than a 40% cure rate 1 . The anti-apoptotic NF-kB signalling pathway is constitutively active in ABC DLBCL owing to oncogenic CARD11 mutations or chronic active B-cell receptor signalling, augmented by inactivation of A20 [5] [6] [7] [8] . A subset of ABC DLBCLs use JAK kinase signalling to activate the transcription factor STAT3, a pathway that synergizes with NF-kB in promoting cell survival 9, 10 . The oncogenic aetiology of this JAK-STAT3 signalling has not been elucidated.
We conducted an RNA interference (RNAi) screen for genes that are required for proliferation and survival of lymphoma cell lines and identified three small hairpin RNAs (shRNAs) targeting MYD88 that were toxic to two ABC DLBCL lines but not to two GCB DLBCL lines ( Supplementary Fig. 1a ). During normal immune responses, MYD88 functions as a signalling adaptor protein that activates the NF-kB pathway after stimulation of toll-like receptors (TLRs) and receptors for IL-1 and IL-18 (refs 2, 3) . MYD88 coordinates the assembly of a multi-subunit signalling complex consisting of various members of the IRAK family of serine-threonine kinases 11 . The initial RNAi screen also identified two shRNAs targeting IRAK1 as toxic for one or both of the ABC DLBCL lines, but not for GCB DLBCL lines. A subsequent screen identified additional MYD88 and IRAK1 shRNAs that were toxic to all five ABC DLBCL lines tested but had little effect on GCB DLBCL, Burkitt's lymphoma, mantle cell lymphoma and multiple myeloma lines (Supplementary Fig. 1a ). Using shRNAs targeting the 39 untranslated regions of MYD88 and IRAK1, which reduced expression of their respective proteins ( Supplementary Fig. 1c ), we showed that ABC DLBCL cells could be rescued from shRNA-mediated toxicity by coexpression of coding region cDNAs (IRAK1, Supplementary Fig.  1d ; MYD88, see below). MYD88 and IRAK1 shRNAs displayed a timedependent toxicity for ABC DLBCL lines and induced apoptosis, but had little effect on GCB DLBCL and myeloma lines ( Fig. 1 and Supplementary Fig. 1b, e) . Together these data establish that MYD88 and IRAK1 are required to maintain the viability of ABC DLBCL cells.
To comprehensively discover somatic mutations in ABC DLBCL, we used high-throughput resequencing of mRNA to search for sequence variants in four ABC DLBCL lines. In addition to known mutations in CARD11 and CD79B, we identified a single nucleotide variant that changed a leucine residue at position 265 of the MYD88 coding region to proline (L265P) in all four ABC DLBCL lines tested. This variant resides in the MYD88 TIR domain, which interacts with TIR domains of various receptors during innate immune responses and also mediates homotypic interactions 12, 13 .
To extend this finding, we resequenced the MYD88 coding region in 382 lymphoma biopsy samples. The L265P mutation was by far the most common variant observed, occurring in 29% of ABC DLBCL biopsies. By contrast, this mutation was rare or absent among DLBCLs of the GCB and PMBL subtypes and among Burkitt's lymphomas (Fig. 2b) . Of note, MYD88 L265P was also observed in 9% of gastric mucosa-associated lymphoid tissue (MALT) lymphomas. Most MYD88 L265P mutations appeared heterozygous by sequencing, but six biopsy samples and one ABC DLBCL line (OCI-Ly3) were homozygous. By array-based comparative genomic hybridization 14 , 56% (15 of 27) of the ABC DLBCL cases with gain or amplification of the MYD88 locus had the L265P mutation, compared to 29% (13 of 45) with wild-type MYD88 copy number (P 5 0.023), indicating selection by the cancer cells for this mutant allele. A host of other, less common MYD88 mutations were equally distributed among ABC and GCB DLBCL cases (Fig. 2a, b) . Whereas most mutations were in the TIR domain, one mutation (V52M) was in the death domain and two were between the death and TIR domains (S149G/I). Six ABC DLBCL lines had a MYD88 mutation (Fig. 1) , whereas all 14 GCB DLBCL lines tested were wild type. In 13 DLBCL cases for which matched germline DNA was available, the MYD88 mutations (L265P, V217F, S219C, M232T, S243N, T294P) were confirmed to be somatically acquired. Overall, MYD88 mutations were observed in 39% of ABC DLBCLs (Fig. 2b) , establishing MYD88 as among the most frequently altered genes in this malignancy.
The MYD88 mutations partially overlapped with abnormalities in CD79B/A, A20 and CARD11 in ABC DLBCL tumours (Fig. 2c) . Among cases with a MYD88 L265P mutation, 34% had a coincident CD79B/A mutation whereas this overlap was significantly less common among ABC DLBCLs without a CD79B/A mutation (18%; P 5 0.03). These data raise the possibility of a functional interaction between the chronic active B-cell receptor signalling that is associated with CD79B/A mutations 8 and the signalling that is instigated by the MYD88 L265P mutation. Some cases had MYD88 L265P as well as a CARD11 mutation, which strongly activates NF-kB, suggesting that the MYD88 mutation confers additional biological attributes beyond NF-kB activation.
The location of the MYD88 mutations within the three-dimensional structure of the MYD88 TIR domain was both surprising and instructive (Fig. 2d) . The L265P mutation occurs at a residue that is invariant in evolution and contributes to a b-sheet at the hydrophobic core of the domain. Another mutation, M232T, affects a methionine that is in an adjacent b-sheet and contacts the leucine affected by L265P. A cluster of mutations were in the 'B-B loop', an evolutionarily conserved region that mediates TIR domain interactions 15 . Two other mutations, S222R and S243N, alter an adjoining face of the TIR domain. Only one mutant affects the opposite side of the TIR domain (T294P), altering the conserved 'box 3' motif that is important in IL-1 signalling 13 . To examine whether the MYD88 mutants confer a gain or loss of function, we performed a complementation experiment in which we knocked down endogenous MYD88 in ABC DLBCL lines and ectopically expressed wild-type or mutant MYD88 coding regions. In ABC 
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DLBCL lines harbouring an L265P mutation, MYD88 L265P rescued the cells after MYD88 knockdown, but wild-type MYD88 was ineffective ( Fig. 2e) , although these MYD88 isoforms were expressed equivalently (data not shown). Hence, these ABC DLBCLs are 'addicted' to the action of the L265P MYD88 mutant, indicating that it is a gain-offunction driver mutation that confers a selective advantage during the evolution of ABC DLBCL tumours.
To assess the biochemical and functional consequences of the MYD88 mutations, we fused green fluorescent protein (GFP) to MYD88 and introduced the fusion proteins into DLBCL lines. Immunoprecipitation of MYD88-GFP with anti-GFP antibodies brought down IRAK1 and IRAK4, two kinases known to associate with MYD88 upon TLR or IL-1 stimulation (Fig. 3a) 3 . During IL-1 signalling, IRAK1 becomes hyperphosphorylated by IRAK4, resulting in slowly migrating IRAK1 isoforms 16 . In cells bearing the MYD88 L265P, a prominent, slowmigrating IRAK1 species co-immunoprecipitated with MYD88 (Fig. 3a) . By contrast, wild-type MYD88 did not associate strongly with these IRAK1 isoforms nor did the other MYD88 mutants tested (Fig. 3b) . Treatment with l-phosphatase collapsed the slow-migrating IRAK1 species into a single band, confirming that they are phosphorylated IRAK1 isoforms (Fig. 3c) . Phosphorylation of endogenous IRAK1 was observed in an ABC DLBCL line with L265P but not in a GCB DLBCL line (Fig. 3c) . Thus, the MYD88 L265P mutant nucleates a signalling complex in ABC DLBCLs that includes phosphorylated IRAK1, consistent with a gain-of-function phenotype.
IRAK4 co-immunoprecipitated with MYD88, but it associated equivalently with wild-type and L265P MYD88 (Fig. 3a) . Knockdown of IRAK4 was toxic for ABC DLBCL lines but not for GCB DLBCL and myeloma lines ( Fig. 3d and Supplementary Fig. 1c ). Wild-type IRAK4 rescued ABC DLBCL lines after IRAK4 shRNA induction, but a kinasedead IRAK4 isoform could not (Fig. 3e) , despite equivalent expression (data not shown). By contrast, IRAK1 kinase activity was not required for the survival of ABC DLBCL cells (Supplementary Fig. 1d) . A selective small-molecule inhibitor of IRAK1 and IRAK4 kinase activity 17 killed ABC DLBCL lines but not GCB DLBCL and myeloma lines (Fig. 3f) . Together, these findings demonstrate that ABC DLBCLs rely upon IRAK4 kinase activity to transduce signals from MYD88 L265P that promote survival.
To investigate signalling pathways that are engaged by MYD88 L265P, we knocked it down in an ABC DLBCL line and profiled the ensuing gene expression changes (Supplementary Table 1 and Supplementary Fig. 2) . We identified 285 genes that were down-modulated after MYD88 knockdown, and searched for overlap between this MDY88 signature and previously defined gene expression signatures 18 (Supplementary Table 2 ). The most significantly enriched signature reflects NF-kB signalling in ABC DLBCL (443 enrichment, P 5 2.4 3 10
2130
). This signature was also inhibited after IRAK1 knockdown ( Supplementary Fig. 3 ), indicating that IRAK1 mediates NF-kB activation by MYD88 L265P. To compare the ability of wildtype and mutant MYD88 isoforms to activate NF-kB, we expressed them as GFP fusion proteins in a GCB DLBCL line with little endogenous NF-kB activity. Whereas wild-type MYD88 activated an NFkB-dependent reporter modestly, L265P had strong activity, as did M232T and S243N, whereas S222R and T294P had an intermediate effect (Fig. 4b) . At all MYD88 expression levels, L265P was superior to wild-type MYD88 in upregulating CD83, a previously established NFkB target in this system 5 (Fig. 4c) . Other MYD88 mutants induced CD83 to varying degrees but all were more active than wild-type MYD88. Thus, mutant MYD88 isoforms can contribute to the constitutive NF-kB activation that typifies ABC DLBCL 19 . A signature of JAK kinase signalling in ABC DLBCL overlapped significantly with the MYD88 signature ( Fig. 4a ; 143 enrichment, P 5 9.6 3 10
239
) and with IRAK1-regulated genes ( Supplementary  Fig. 3b ). This was notable because autocrine secretion of IL-6 and IL-10 drives JAK-STAT3 signalling in a subset of ABC DLBCLs 9 .
MYD88 knockdown significantly diminished the secretion of IL-6 and IL-10 as well as the phosphorylation of STAT3 in several ABC DLBCL lines (Fig. 4d, e and Supplementary Fig. 1f ). IL-6 and IL-10 secretion was also blocked by the IRAK1/4 kinase inhibitor, indicating that IRAK4 links MYD88 L265 signalling to the expression of these cytokines (Fig. 3g) . Previous work identified a 'STAT3-high' subgroup of ABC DLBCL tumours with autocrine IL-6/IL-10 signalling and STAT3 phosphorylation, which was missing in a 'STAT3-low' subgroup 9 . The MYD88 L265P mutation was significantly more common in the STAT3-high subgroup (37%) than in the STAT3-low subgroup (13%) (P 5 0.0036), and other MYD88 mutations were modestly enriched among STAT3-high cases as well (Fig. 4f) . These data indicate that 
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MYD88 mutations contribute to JAK-STAT3 signalling in ABC DLBCL tumours.
The MYD88 signature included a number of genes that are induced by type I interferon ( Fig. 4a ; 73 enrichment, P 5 4.3 3 10 210 ), which is intriguing given that MYD88 signalling can induce interferon (IFN)-b production by innate immune cells. IFN-b was measurable in the supernatant of the OCI-Ly3 ABC DLBCL line, and MYD88 knockdown diminished its secretion (Fig. 4d) . MYD88 knockdown decreased IFN-b mRNA levels in the HBL1 line ( Supplementary Fig. 2 ), although IFN-b secretion was below the detection limit. Future work should address whether the secretion of immunomodulatory cytokines such as IFN-b, IL-6 and IL-10 influences immune cells in the microenvironment of ABC DLBCL tumours.
Given the pleiotropic action of MYD88 L265P, we investigated whether MYD88 signalling cooperates with B-cell receptor signalling to maintain ABC DLBCL survival. Knockdown of MYD88 enhanced the killing of an ABC DLBCL line with chronic active BCR signalling by CD79B or CARD11 shRNAs (Fig. 4g ). This finding indicates that MYD88 and B-cell receptor signalling provide non-redundant survival signals to ABC DLBCL cells, in keeping with the fact that some ABC DLBCL tumours harbour MYD88 L265P as well as CD79B or CARD11 mutations (Fig. 2c) .
Our genetic and functional data establish a new oncogenic pathway in lymphomagenesis. Somatically acquired MYD88 mutations in ABC DLBCL promote NF-kB and JAK-STAT3 signalling, which mediate cell survival in this lymphoma type 9, 19 . MYD88 L265P was the most biologically potent mutant and was unique in its ability to coordinate a stable signalling complex containing phosphorylated IRAK1, which probably accounts for its high recurrence among lymphomas. MYD88 L265P also genetically links MALT lymphoma with ABC DLBCL, two lymphoma subtypes that share other oncogenic features 7, 14, [20] [21] [22] . Other MYD88 mutations may also be drivers of lymphomagenesis given their recurrent nature and ability to activate NF-kB. From a therapeutic standpoint, the signalling complex coordinated by MYD88 L265P represents an enticing target. Our study also provides a genetic method to identify patients whose tumours may depend upon MYD88 signalling and who may therefore benefit from therapies targeting IRAK4 alone or in combination with agents targeting the B-cell receptor 8 , NFkB 23, 24 or JAK-STAT3 pathways 9 .
METHODS SUMMARY
RNAi screens, doxycycline-inducible shRNA expression and shRNA toxicity assays were described previously 25 . RNA interference screening results are listed in Supplementary Table 3 . The sequences of individual shRNAs described in the figures are given in Supplementary Table 4 . Gene expression profiling data have been submitted to GEO under accession number GSE22900.
Pre-treatment tumour biopsies were obtained from patients with de novo DLBCL, Burkitt's lymphoma and gastric MALT lymphoma. Samples were analysed as per a protocol approved by the National Cancer Institute Institutional Review Board. Assignment of DLBCL specimens to subtypes was performed as described 1 . Highthroughput RNA sequencing was accomplished using an Illumina GAIIx instrument. C15orf27  CD22  FCRL4  GADD45B  GRAMD1B  ICAM1  IL10  KCNN4  LAT2   ADAR  ALDH1B1  CD69  CMPK2  DDX60  GBP1  HERC6  EPSTI1  IFI44L  IFIT3  IL6   ASS1  KLHDC7B  TYMP   LRRC32  MCM7  NAMPT  NR1D2  OSM  RGS16  RPL7L1  SCLY  SGK1  SNRPB  SOCS3  TCOF1 IFIT1  IRF7  MX1  OAS2  PMAIP1  XAF1  ADAD2  ADAM8  APBB2  B3GNT7  BBS5  C10orf93  C17orf51  C6orf58  CCDC28B  CCND2  CCR7  CD80  EBI3  EIF5AL1  EPHB1  FEZ1  FRMD4A  GLDC  GRPEL1  HCK  IL4I1  LYPLA2  MREG  MVK  MYO7A  PA2G4  PDGFRL  PES1  PLK3  PMP22   POU5F1  PSMD11  PTGER4  PTGES3  RAB39  RAB7L1  RASGRP1  RASSF4  RGL1  RHEBL1  RNF183  RPS6KB2  SLC16A9  SLC39A3  SNRPD3  SNX18  SRF  SSTR2  TAGLN2  TGM1  TMEM109  TMPRSS6  TNF  TNFAIP3  TNFAIP6  TNFRSF21  TRAF1  TSR2  TTC39C  USP18  USP41  WDR46 C9orf102  CCDC86  ELF3  GAS6  GRB10  HLF  HMBS  IL2RB  KLHDC4  PDAP1  PNMA6A  PRR7  SLC12A8  TMEM49 b, MYD88 mutants constitutively activate NF-kB. BJAB cells co-expressing the indicated MYD88-GFP mutants and a NF-kB-driven luciferase reporter construct were assayed for luciferase activity, which was normalized to the expression levels of each MYD88-GFP isoform. a.u., arbitrary units. c, Correlation of MYD88 protein levels with CD83 expression. BJAB cells bearing GFP-tagged MYD88 isoforms were assessed for CD83 and GFP expression. Cells were assigned to equally sized bins based on their GFP levels, and the mean fluorescence intensity (m.f.i.) of CD83 in each bin was plotted. d, MYD88 knockdown decreases cytokine secretion in ABC DLBCL. MYD88 or control (ctrl) shRNAs were induced in ABC DLBCL lines, and the indicated cytokines were measured in the supernatant over time. e, STAT3 phosphorylation in ABC DLBCL depends on MYD88. MYD88 or control (ctrl) shRNAs were induced in ABC DLBCL lines, and cells were assessed by immunoblotting for phosphorylated STAT3 (pY-STAT3), total STAT3, MYD88 and b-actin. f, Preferential association of MYD88 mutant isoforms with the STAT3-high subgroup of ABC DLBCL tumours. See text for details. g, MYD88 and B-cell-receptor signalling pathways cooperate to maintain ABC DLBCL survival. OCI-Ly10 ABC DLBCL cells were first transduced with retroviruses expressing MYD88 or control shRNAs and then infected with retroviruses expressing CD79A, CARD11, or control shRNAs along with GFP. The relative viability of GFP 1 cells is plotted, normalized to day 0 values. All error bars are s.e.m. (n 5 3).
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Cell lines. Cell lines were cultured in RPMI 1640 medium supplemented with penicillin/streptomycin and 10% fetal bovine serum or, for the OCI series of cell lines, Iscove's medium with 20% fresh human plasma. Cells were maintained in a humidified, 5% CO 2 incubator at 37 uC. All cell lines were engineered to express an ecotropic retroviral receptor and the bacterial tetracycline repressor as previously described 25 . Retroviral vectors and retroviral transduction. A previously described retroviral vector, pRSMX 25 , was used to express shRNA for the library screen. A modified version of this vector, pRSMX-PG, in which the puromycin selectable marker was fused with the green fluorescence protein (GFP), was used to co-express shRNA and GFP for shRNA toxicity assay. Retroviral transduction was performed by transfecting the retroviral vector and a mixture of helper plasmids for a mutant ecotropic envelope and gag and pol into 293T cells using Lipofectamine 2000 (Invitrogen). Retroviral supernatants were harvested 48 h after transfection and were used to transduce ecotropic receptor-expressing target cells by centrifugation at 2,500 r.p.m. for 1.5 h in the presence of 8 mg ml 21 polybrene. shRNA library screening. Pools of shRNA library were screened as previously described 25 . Briefly, pools of roughly 1,000 shRNA expressing retroviral vectors were used to transduce target cell lines. After puromycin selection, stable integrants were induced to express shRNA by doxycycline (20 ng ml 21 ). Parallel uninduced cultures were kept as control. After 3 weeks of shRNA induction, genomic DNA from both uninduced and induced cultures were harvested. shRNA-associated bar code sequences from the genomic DNA were PCR amplified and in vitro transcribed, as described 25 . The transcribed RNA products were labelled fluorescently with either Cy5 (induced) or Cy3 (uninduced) using the Universal Linkage System (Amersham Biosciences) and hybridized onto microarrays containing DNA oligonucleotides complementary to the bar code sequences, as described 25 . Each bar code experiment was performed in quadruplicate, and the microarray results for each bar code were averaged. The complete screening results are presented in Supplementary Table 3 , which includes some data that have been previously published 8, 25 . shRNA sequences. The shRNA sequences used in individual experiments are listed in Supplementary Table 4 . shRNA toxicity and complementation assays. shRNA toxicity was assayed as described 25 . Briefly, the pRSMX-PG vector that co-expresses shRNA and GFP was transduced into lymphoma and multiple myeloma cell lines. Two days after retroviral transduction, doxycycline was added to induce shRNA expression. The fraction of GFP , shRNA-expressing fraction at later time points indicates shRNA toxicity. Complementation studies were performed in the DLBCL cell line that harbours the MYD88 L265P mutation. HBL1 cells were transduced with retroviral vectors that co-express GFP and shRNA targeting the 39 UTR of MYD88 (or IRAK1). shRNA-transduced cells were subsequently infected with retroviruses co-expressing wild-type or mutant MYD88 (or IRAK1) coding regions and mouse CD8 (Lyt2). The cell fraction positive for GFP and CD8 (using anti-mouse CD8a, BD Pharmingen) was monitored over time by flow cytometry as above. TMD8 and OCI-Ly3 cells were first transduced with retroviruses coexpressing wild-type or mutant MYD88 (or IRAK1) coding regions and mouse CD8 (Lyt2) and enriched for Lyt2 expression with magnetic beads. Enriched cells were subsequently infected with retroviral vectors that co-express GFP and an shRNA targeting the 39 UTR of MYD88. The cell fraction positive for GFP and CD8 was monitored over time by flow cytometry.
For the IRAK4 complementation assay, HBL1, HLY1, TMD8 and SUDHL2 lymphoma cell lines were first retrovirally transduced with either vLyt2 empty vector, or vLyt2 vector expressing wild-type or kinase-dead IRAK4 (K213A/ K214A). The infected cells were later enriched using the CD8 microbeads method (Miltenyi Biotec) according to manufacturer's protocol. The enriched cells were then infected with retroviral vector pRSMX-PG expressing either a control shRNA or an IRAK4 shRNA. Doxycycline was added 2 days after infection to induce shRNA expression. The fraction of GFP-positive cells was monitored over time by FACS analysis and the decline of GFP hence shRNA expressing cells indicates toxicity. Synergistic toxicity of MYD88 and either CARD11 or CD79A knockdown. OCI-Ly10 cells were first infected with either pRSMX-puro empty vector or pRSMX-puro vector encoding MYD88 shRNA sequence (59-GTACCAGT ATTTATACCTCTA-39). Two days after infection the two cells lines were selected using 1 mg ml 21 puromycin. The selected cells were then retrovirally infected with pRSMX-PG encoding either a scramble control, shRNA sequence against CARD11 (target sequence 59-GGGGTGTGTACCAGGCTATGA-39) or CD79A (target sequence 59-GGGGCTTCCTTAGTCATATTC-39). Doxycycline was added 2 days after infection to induce shRNA expression. The fraction of GFPpositive cells was monitored over time by FACS analysis and the decline of GFP hence shRNA expressing cells indicates toxicity. High-throughput RNA sequencing/PCR amplification/Sanger sequencing. The standard Illumina pipeline for RNA-seq was used, using paired-end 75-base-pair runs with each sample run in one sequencing lane, yielding ,20 million reads per sample. Sequences were mapped back to both RefSeq and Ensemble transcript models using the BWA algorithm 26 , yielding a median resequencing coverage of 103. Single nucleotide variants (SNVs) were reported that deviated from the human reference genome sequence, were observed in both sequencing directions, represented .20% of the resequencing coverage at a particular base pair position, and were not known SNPs in the dbSNP database of NCBI. A total of 52,160 putative SNVs was detected in the four ABC DLBCL cell lines studied. Sequences have been submitted to the NCBI short sequence archive under accession SRP003192. On the basis of the criteria above, all SNVs that are not represented in publically available databases of single nucleotide polymorphisms (SNPs) are listed in Supplementary Sanger sequencing of MYD88 was accomplished with the following primers: MYD88-Full-F, 59-GACCTCTCCAGATCTCAAAAGGCAGATTCC-39 (PCR amplification and sequencing, exon 1); MYD88-Full-R, 59-GCAGAAGTACAT GGACAGGCAGACAGATAC-39 (PCR amplification and sequencing, exon 5); MYD88-Seq-E1R, 59-TCTCTCCATGGGAGACAGGATGCTG-39 (sequencing exon 1); MYD88-Seq-E2F, 59-TGGGTAAAGAGGTAGGCACTCCCAG-39 (sequencing exon 2); MYD88-Seq-E2R, 59-GCCCATCTGCTTCAAACACCCATGC-39 (sequencing exon 2); MYD88-Seq-E3F, 59-AAGCCTTCCCATGGAGCTCTGAC CAC-39 (sequencing exon 3); MYD88-Seq-E3R, 59-GCTAGGAGGAGATGCCC AGTATCTG-39 (sequencing exon 3); MYD88-Seq-E4F, 59-ACTAAGTTGC CACAGGACCTGCAGC-39 (sequencing exon 4); MYD88-Seq-E4R, 59-ATCCA GAGGCCCCACCTACACATTC-39 (sequencing exon 4); MYD88-Seq-E5F, 59-GTTGTTAACCCTGGGGTTGAAG-39 (sequencing exon 5).
For 155 cases of ABC DLBCL, analysis of CARD11, CD79B, and A20 by Sanger sequencing was performed as described 5, 8, 27 . A20 was declared epigenetically silenced if the expression level in a case was more than 2 standard deviations below the mean of other ABC DLBCL cases, based on previous gene expression profiling data 1 . Deletion of the A20 locus (TNFAIP3) was analysed by quantitative PCR using primers to amplify exon 3 and exon 6, as described 27 , and compared to a reference gene, CHMP4A, that is not subject to copy number alterations in ABC DLBCL. A20 was declared deleted if one or both of the A20 PCR products had an estimated copy number that was more than 3 standard deviations below the average of 9 normal control DNA samples. The following quantitative PCR primers were used: CHMP4A-F, 59-CTGCAAGGGAGGAGGGGTTTCATTC-39 (qPCR control gene); CHMP4A-R, 59-CTTGGGTGTTCCTTCTGGCCAGTC-39 (qPCR control gene); A20-E3F, 59-ACCTTTGCTGGGTCTTACATGCAG-39 (qPCR A20); A20-E3R, 59-TAT GCCCACCATGGAGCTCTGTTAG-39 (qPCR A20); A20-E6F, 59-TGAGATC TACTTACCTATGGCCTTG-39 (qPCR A20); A20-E6R, 59-TCAGGTGGCTGA GGTTAAAGACAG-39 (qPCR A20). Expression vectors and cDNA mutagenesis. The expression vector, vLyt2-MYD88-EGFP, encoding carboxy terminus EGFP-tagged MYD88 was constructed by three-way ligation of PCR-generated MYD88 and EGFP products into the pBMN-IRES-Lyt2 vector (provided by G. Nolan). The restriction site SalI was included in the MYD88 PCR reverse primer and the EGFP PCR forward primer to facilitate the ligation between MYD88 and EGFP. MYD88 or EGFP PCR products were generated using the following primer pairs: 59-TAGTAGGGATCCG CCGCCACCATGCGACCCGACCGCGCTGA-39 (MYD88), 59-TAGTAGGTC GACGGGCAGGGACAAGGCCTTGGC-39 (MYD88), 59-TAGTAGGTCGACA TGGTGAGCAAGGGCGAGGAG-39 (EGFP), 59-TAGTAGGCGGCCGCTTA CTTGTACAGCTCGTCCAT-39 (EGFP).
The expression vector vLyt2-AU1-MYD88 encoding amino terminus AU1-tagged MYD88 was constructed by inserting PCR-generated MYD88 into the pBMN-IRES-Lyt2 vector. MYD88 PCR product was generated using the following primers: 59-TAGTAGGGATCCGCCGCCACCATGGACACATACCGCTACA TCCGACCCGACCGCGCTGAGGCT-39 and 59-TAGTAGGCGGCCGCTCAG GGCAGGGACAAGGCCTTGGC-39.
IRAK1 expression vectors were similarly created by inserting PCR-generated IRAK1 cDNAs (from pIND-IRAK1 wild type and K239A kinase-dead templates, a gift from X. Li) into the pBMN-IRES-Lyt2 vector, using the following PCR primers: 59-TAGTAGCTCGAGGCCGCCACCATGGCCGGGGGGCCGGGC-39 and 59-TAGTAGGCGGCCGCTCACTTGTCATCGTCGTCCTTGTAGTCGC TCTGAAATTCATCACTTTC-39.
IRAK4 expression vectors were generated by inserting PCR-generated IRAK4 cDNA (from a template obtained from the Dana-Farber/Harvard Cancer Center RESEARCH LETTER
